11 completed, 8 terminated, 6 recruiting, 2 active not recruiting. 28 Phase 1, 9 Phase 2, 1 Early Phase 1.
Follow Other Solid Tumors: new trials by email Literature Review of Other Solid Tumors trials Research Report on Other Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors Chimeric receptor T-cells + Trastuzumab, Fludarabine and Cyclophosphosphamide - HER2+ Advanced Breast Cancer, Other Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | National University Hospital, Singapore | 36 | 2026-11-01 | 2025-09-23 |
| NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors Natural history study of individuals with very rare tumors - Very Rare Tumors, Very Rare Cancers | Recruiting | National Cancer Institute (NCI) | 4000 | 2026-11-01 | 2026-10-27 | |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors BL-M05D1 - Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | SystImmune Inc. | 160 | 2025-07-30 | 2026-08-05 |
| A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors DXC008 - Prostate Cancer, Other Solid Tumors | Phase 1 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 110 | 2025-05-15 | 2026-09-23 |
| Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors ABO2102, Toripalimab - Pancreatic Neoplasms, Other Solid Tumors | Early Phase 1 | Recruiting | Ruijin Hospital | 56 | 2024-09-24 | 2025-05-21 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors KD6001, Tislelizumab, Bevacizumab - Advanced HCC, Other Solid Tumors | Phase 1 / Phase 2 | Unknown | Shanghai Kanda Biotechnology Co., Ltd. | 85 | 2024-04-15 | 2024-01-10 |
| CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers CRTE7A2-01 TCR-T cell therapy - Cervical Cancer, Anal Cancer | Phase 1 | Not yet recruiting | Corregene Biotechnology Co., Ltd | 24 | 2024-04-15 | 2024-04-10 |
| TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib - Osteosarcoma, Other Solid Tumors | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 20 | 2024-02-15 | 2025-12-12 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Terminated | Evopoint Biosciences Inc. | 12 | 2023-09-20 | 2026-07-23 |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation NT-175 - Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | AstraZeneca | 45 | 2023-07-12 | 2026-09-29 |
| A Study of CDX-585 in Patients With Advanced Malignancies CDX-585 - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Celldex Therapeutics | 20 | 2023-05-11 | 2025-06-15 |
| Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors BL-M07D1 - Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 26 | 2023-01-05 | 2026-08-27 |
| A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor GB263T - NSCLC, Other Solid Tumors | Phase 1 / Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 120 | 2022-05-17 | 2022-08-05 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) HC-7366 - Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer | Phase 1 | Terminated | HiberCell, Inc. | 35 | 2022-02-23 | 2024-03-08 |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors BL-B01D1 - Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | Phase 1 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 4 | 2022-02-15 | 2025-09-26 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) HC-5404-FU - Renal Cell Carcinoma, Gastric Cancer | Phase 1 | Completed | HiberCell, Inc. | 23 | 2021-06-08 | 2024-03-08 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies CDX-527 - Non-small Cell Lung Cancer, Breast Cancer | Phase 1 | Completed | Celldex Therapeutics | 27 | 2020-08-04 | 2023-06-18 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 17 | 2020-07-14 | 2025-05-20 |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
Showing 20 of 31. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Colorectal Neoplasms (8) · Melanoma (8) · Ovarian Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Renal Cell (6) · Squamous Cell Carcinoma of Head and Neck (5) · Head and Neck Neoplasms (4) · Stomach Neoplasms (4) · Cholangiocarcinoma (3) · Esophageal Neoplasms (3) · Fallopian Tube Neoplasms (3) · Liver Neoplasms (3) · Pancreatic Neoplasms (3) · Carcinoma, Pancreatic Ductal (2)
Neoplasms (24) · Neoplasms by Site (23) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (15) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Bronchial Neoplasms (13) · Carcinoma (13) · Carcinoma, Bronchogenic (13) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Thoracic Neoplasms (13)
pembrolizumab (3) · spartalizumab (2) · Bevacizumab (1) · Bortezomib (1) · Crizotinib (1) · Dexamethasone (1) · Docetaxel (1) · Drug Therapy (1) · IFL protocol (1) · Injections (1) · Protein Kinase C (1) · Radiation Dose Hypofractionation (1) · Solutions (1) · Trastuzumab (1) · WW Domain-Containing Oxidoreductase (1)
Celldex Therapeutics (3) · Novartis Pharmaceuticals (3) · HiberCell, Inc. (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · AbbVie (1) · Allist Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Corregene Biotechnology Co., Ltd (1) · Evopoint Biosciences Inc. (1) · Genor Biopharma Co., Ltd. (1) · Hangzhou DAC Biotechnology Co., Ltd. (1) · IDEAYA Biosciences (1) · Jacobio Pharmaceuticals Co., Ltd. (1) · Karyopharm Therapeutics Inc (1)
United States (17) · China (8) · Canada (4) · Germany (3) · Spain (3) · Australia (2) · France (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · South Korea (2) · Switzerland (2) · Bulgaria (1) · Hungary (1)
Jose Iglesias, MD (2) · Baiyong Shen (1) · Christopher Barker, MD (1) · George Cole Jr., MD (1) · Jian Zhang, PHD (1) · Jun Guo, PHD (1) · Li Zhang, M.D. (1) · Mary F Wedekind Malone, D.O. (1) · Sarah Tannenbaum (1)
PMID 22547604, PMID 31145415, PMID 32179633, PMID 32364844, PMID 32372416, PMID 32522887, PMID 34694529, PMID 39671539
2015 (2), 2014 (1), 2016 (1)